ELB041 (Anti-CD115 antibody in oncology)
Antibody targeting macrophages, immune-suppressive accomplices of cancer cells Status: candidate for the clinic selected
In 2016, ELSALYS BIOTECH acquired the development and marketing rights for an anti-CD115 TG3003 (now called ELB041) from TRANSGENE. This antibody is directed against the receptor for the M-CSF (Macrophage Colony-Stimulating Factor), a factor that drives survival and differentiation of myeloid cells. In particular, CD115 (or M-CSFR) directs their differentiation into macrophages, whose presence in the tumour microenvironment is associated with poor prognosis. A number of studies has now established that within the population of macrophages, the M2 subpopulation has a key role in promoting tumour progression. The new wave of immuno-oncology antibodies should therefore aim at targeting tumour associated macrophages (Nielsen & Schmid 2017, Mantovani et al, 2017).
ELB041 has a unique mode of action: in reprogramming macrophage differentiation, it lifts the immune suppression exerted by M2 macrophages while preventing the potentially toxic accumulation of M-CSF in the bloodstream.
ELB041 could become a valuable treatment option for cancers with poor prognosis associated to high infiltration of M2 macrophages, such as breast, stomach, ovarian, kidney and head and neck cancers.